Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Prelude Therapeutics
Biotech
Metsera sale architect swings to Structure—Chutes & Ladders
Metsera acquisition architect swings to Structure. Vir CMO exits after less than 2 years. Leal reels in Big Pharma vets to exec team.
Darren Incorvaia
,
Zoey Becker
,
Will Maddox
Apr 17, 2026 10:10am
Prelude loses CMO, pauses SMARCA2 degraders, scores Incyte cash
Nov 4, 2025 9:40am
Prelude calls it curtains on lead SMARCA2 cancer asset
Aug 14, 2025 10:44am
Pathos AI's $365M series D to fund trial of Novo tumor drug
May 15, 2025 10:20am
Prelude thinks SMARCA with AbCellera deal, culls 2 candidates
Nov 2, 2023 8:06am
3 more biotechs look to cull, partner assets
Nov 14, 2022 11:40am